Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Impact of Escitalopram on Sperm DNA Fragmentation
NCT03527043 · Weill Medical College of Cornell University · PHASE2 · terminated · last registry update 2025-08-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “funding stopped” | – | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-05Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebo (NCT07747389)
- 2026-07-14Also stopped (suspended): National Institute of Allergy and Infectious Diseases (NIAID), Pramipexole ER + Escitalopram (NCT06705478)
- 2026-07-10Also stopped (withdrawn): University of Minnesota, Metformin + Metformin (NCT07007221)
- 2026-07-09Results posted on the registry: Massachusetts General Hospital, Aripiprazole + Venlafaxine XR (NCT02977299)
- 2026-06-30Also stopped (suspended): Global Coalition for Adaptive Research, Intervention A Fluoxetine Hydrochloride (HCl) + Intervention A Placebo (NCT05422612)
- 2026-06-11Results posted on the registry: University of California, Los Angeles, a drug against SLC6A4 (NCT05162391)
- 2026-06-09Results posted on the registry: RAND, Antidepressant Therapy (NCT04777006)
- 2026-06-03Phase 3 first posted: Eric Lenze, Lumateperone + Placebo (NCT07623135)
- 2026-06-03Results posted on the registry: University of Utah, Progesterone + Placebo (NCT05128071)
- 2026-05-27Results posted on the registry: University of Washington, a drug against SLC6A4 (NCT06027814)
- 2026-05-20Also stopped (suspended): Global Coalition for Adaptive Research, Intervention A Fluoxetine Hydrochloride (HCl) + Intervention A Placebo (NCT05948553)
- 2026-05-12Also stopped (terminated): University of Wisconsin, Madison, Psilocybin (NCT05322954)
- 2026-05-04Also stopped (withdrawn): University of Southern California, Trazodone + Quetiapine (NCT05085808)
- 2026-04-23Results posted on the registry: University of Chicago, Caplyta + Placebo (NCT05356013)
- 2026-04-16Results posted on the registry: University of California, Irvine, Nortriptyline + Topiramate + Verapamil + Paroxetine (NCT04404439)
- 2026-04-14Results posted on the registry: University of Florida, Fluoxetine + Calcium (NCT04850222)
- 2026-04-09Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05697835)
- 2026-04-09Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05575128)
- 2026-03-31Results posted on the registry: Washington University School of Medicine, a drug against SLC6A4 (NCT05685511)
- 2026-03-19Results posted on the registry: Duke University, 5% lidocaine/5 mg/ml 0.02% estradiol compound cream + Nortriptyline (NCT03844412)
- 2026-01-29Results posted on the registry: Friends Research Institute, Inc., a drug against SLC6A4 (NCT03884946)
- 2026-01-23Results posted on the registry: Hanoi Medical University, a drug against SLC6A4 (NCT04706624)
- 2026-01-21Also stopped (terminated): Shanghai Mental Health Center, conventional medical treatment (TAU) (NCT05528224)
- 2026-01-16Results posted on the registry: Ryan M. Carnahan, a drug against SLC6A4 (NCT04449055)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision